Details:
Vabysmo (faricimab-svoa) is the first bispecific antibody approved for the eye. It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A).
Lead Product(s): Faricimab-svoa
Therapeutic Area: Ophthalmology Product Name: Vabysmo
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2023
Details:
Faricimab is the first investigational bispecific antibody designed for the eye) It targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) – that drive a number of retinal conditions.
Lead Product(s): Faricimab
Therapeutic Area: Ophthalmology Product Name: RG7716
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Details:
First patient is dosed in a 370-patient in Phase 3 trial of APP13007 in the US. Sosei Heptares will receive undisclosed milestone payments based on progression of Activus' pipeline and royalties from the commercialization of certain products should they reach the market.
Lead Product(s): Clobetasol Propionate
Therapeutic Area: Ophthalmology Product Name: APP13007
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Formosa Laboratories
Deal Size: $8.5 million Upfront Cash: Undisclosed
Deal Type: Agreement March 11, 2021
Details:
Cyclosporine topical ophthalmic emulsion, 0.1% is an investigational treatment for severe VKC in patients ages 4-18. U.S. Food and Drug Administration (FDA) has accepted its NDA submission which is supported by robust data from VEKTIS trial.
Lead Product(s): Cyclosporine
Therapeutic Area: Ophthalmology Product Name: NOVA22007
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
The study demonstrated for the first time that 7-day levofloxacin/dexamethasone eye drops were as effective as 14-day tobramycin/dexamethasone eye drops to treat ocular inflammation and prevent infection in post-cataract surgery patients.
Lead Product(s): Levofloxacin,Dexamethasone
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2020
Details:
Kubota has completed subject enrollment in its ongoing Phase 3 clinical trial investigating emixustat hydrochloride in patients with macular atrophy secondary to Stargardt disease.
Lead Product(s): Emixustat Hydrochloride
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2020
Details:
The company has achieved over 65% subject enrollment in its ongoing phase 3 clinical trial investigating emixustat hydrochloride in patients with macular atrophy secondary to Stargardt disease.
Lead Product(s): Emixustat Hydrochloride
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2020
Details:
This publication supports the rationale for investigating emixustat in the treatment of Stargardt disease and diabetic retinopathy.
Lead Product(s): Emixustat Hydrochloride
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2020